Compare PCRX & WLDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | WLDN |
|---|---|---|
| Founded | 2006 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.6B |
| IPO Year | 2011 | 2006 |
| Metric | PCRX | WLDN |
|---|---|---|
| Price | $24.39 | $106.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $32.86 | ★ $117.00 |
| AVG Volume (30 Days) | ★ 840.5K | 193.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.17 |
| EPS | 0.47 | ★ 2.79 |
| Revenue | ★ $716,791,000.00 | $651,926,000.00 |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $9.53 | $9.01 |
| P/E Ratio | $51.90 | ★ $38.23 |
| Revenue Growth | 3.14 | ★ 12.90 |
| 52 Week Low | $18.17 | $30.43 |
| 52 Week High | $27.64 | $121.00 |
| Indicator | PCRX | WLDN |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 52.29 |
| Support Level | $25.56 | $103.48 |
| Resistance Level | $26.70 | $115.00 |
| Average True Range (ATR) | 1.03 | 4.44 |
| MACD | -0.19 | -0.55 |
| Stochastic Oscillator | 9.97 | 36.43 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.